SPRINT研究:FGF23与CKD老年人的衰弱及跌倒
该研究基于SPRINT试验中2376例eGFR<60 mL/min/1.73 m²的CKD老年人,分析完整FGF23与衰弱、跌倒的横断面及纵向关联。校正多因素后,FGF23每升高一倍,衰弱比值比为1.34(95%CI 1.01-1.77),跌倒风险比为1.99(95%CI 1.48-2.68)。
要点
- CKD老年人FGF23升高与现患衰弱独立相关(OR 1.34)。
- FGF23最高四分位者跌倒风险是最低四分位者的2.32倍。
- FGF23每翻倍,跌倒风险增加约一倍(HR 1.99)。
核心结论
- 在SPRINT合并CKD的老年参与者中,完整FGF23与现患衰弱及跌倒相关。
研究设计与样本
- 横断面与纵向观察性研究,样本为SPRINT试验中2376例eGFR<60 mL/min/1.73 m²的CKD参与者。
- SPRINT为随机试验,比较标准(SBP<140 mm Hg)与强化(SBP<120 mm Hg)降压对无糖尿病老年人心血管和认知结局的影响。
主要发现
- 校正 demographics、合并症、随机分组、降压药、eGFR、矿物质代谢标志物及衰弱后,FGF23每升高一倍,现患衰弱相对非衰弱的OR为1.34(95%CI 1.01-1.77)。
- FGF23最高四分位较低最低四分位的跌倒风险HR为2.32(95%CI 1.26-4.26)。
- FGF23每升高一倍的跌倒风险HR为1.99(95%CI 1.48-2.68)。
关键数值与推荐
- 暴露变量为完整FGF23,采用多项logistic回归分析横断面衰弱关联,Cox比例风险分析纵向跌倒关联。
- CKD定义为eGFR<60 mL/min/1.73 m²;血压分组标准为SBP<140 mm Hg与SBP<120 mm Hg。
临床怎么用
- 对CKD老年人可关注FGF23水平,作为衰弱与跌倒风险的潜在评估线索。
- FGF23升高者或需加强衰弱筛查与跌倒预防,但因果与干预价值尚待验证。
局限性
- 为观察性分析,无法确立FGF23与衰弱、跌倒的因果关系。
- 研究人群限于SPRINT中无糖尿病的CKD老年人,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Chronic kidney disease (CKD) is associated with frailty. Fibroblast growth factor 23 (FGF23) is elevated in CKD and associated with frailty among non-CKD older adults and individuals with human immunodeficiency virus. Whether FGF23 is associated with frailty and falls in CKD is unknown. DESIGN: Cross-sectional and longitudinal observational study. SETTING: Systolic Blood Pressure Intervention Trial (SPRINT), a randomized trial evaluating standard (systolic blood pressure [SBP] <140 mm Hg) versus intensive (SBP <120 mm Hg) blood pressure lowering on cardiovascular and cognitive outcomes among older adults without diabetes mellitus. PARTICIPANTS: A total of 2,376 participants with CKD (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 ). MEASUREMENTS: The exposure variable was intact FGF23. We used multinomial logistic regression to determine the cross-sectional association of intact FGF23 with frailty and Cox proportional hazards analysis to determine the longitudinal association with incident falls. Models were adjusted for demographics, comorbidities, randomization group, antihypertensives, eGFR, mineral metabolism markers, and frailty. RESULTS: After adjustment, the odds ratio for prevalent frailty versus non-frailty per twofold higher FGF23 was 1.34 (95% confidence interval [CI] = 1.01-1.77). FGF23 levels in the highest quartile versus the lowest quartile demonstrated more than a twofold increased fall risk (hazard ratio [HR] = 2.32; 95% CI = 1.26-4.26), and the HR per twofold higher FGF23 was 1.99 (95% CI = 1.48-2.68). CONCLUSION: Among SPRINT participants with CKD, FGF23 was associated with prevalent frailty and falls.
引用
- Jovanovich A, Ginsberg C, You Z, et al. FGF23, Frailty, and Falls in SPRINT. J Am Geriatr Soc. 2020. PMID: 33289072. doi:10.1111/jgs.16895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。